Articles tagged with Drug Studies
Research found that community-dwelling older adults with advanced age, frailty, or multiple prescription medications had greater net benefits from intensive blood pressure lowering. However, this approach can increase treatment-related harms in these groups.
Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa, a group of rare and severe skin disorders. The licensing agreement includes collaboration with Theravia to develop, register and commercialise the drug.
A new study found that generic drugs made in India have significantly more 'severe adverse events' for patients, including hospitalization and death. The researchers matched 2,443 drugs made in the US and emerging economies, finding that mature generic drugs were responsible for the higher rates of severe adverse events.
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.
A study by University of Bath researchers found that stopping anticoagulants for patients aged 75 and over does not significantly affect the risk of major bleeding, but increases the risk of serious events like stroke and death. This highlights the need for clinicians to carefully consider the risks of stopping anticoagulation therapy ...
A new clinical trial will evaluate whether adding ketamine to standard treatment can improve outcomes for patients suffering from status epilepticus. The trial, called KESETT, hopes to determine whether ketamine can terminate the seizures in more patients than current treatments.
A new medication approved to treat type 2 diabetes and kidney disease also significantly reduces the risk of heart attacks and strokes among these patients. Sotagliflozin, a sodium-glucose cotransporter inhibitor, blocks proteins that help control blood sugar levels and has been shown to reduce cardiovascular events by 23%.
The Colorectal Cancer Alliance has awarded new grants to researchers, convened top scientists at the Cure CRC Summit, and launched K-SPY, a groundbreaking multi-center platform trial for high-risk colorectal cancer cases. The initiative aims to improve outcomes for millions affected by the disease.
A clinical trial found that semaglutide significantly reduced weekly alcohol craving, drinking quantity, and the frequency of heavy drinking days in adults with symptoms of alcohol use disorder. Participants who received semaglutide also consumed lower amounts of alcohol during laboratory tests.
Researchers found that bimagrumab increases bone tissue while building muscle mass, reducing the risk of osteoporosis. The study suggests bimagrumab could be part of a second-generation weight loss drug on the market.
Researchers at Fujita Health University have developed a novel therapy using mesenchymal stem cells to treat inflammatory eye diseases, reducing inflammation and promoting tissue repair. The study found that adMSC injections effectively reduced inflammation in mice with GVHD without long-term complications.
Researchers at the University of Cincinnati presented studies on intracerebral hemorrhage treatment eligibility, finding only 3% of patients are eligible for a minimally invasive procedure. Additionally, a study found racial disparities in stroke recovery, with Black individuals experiencing worse functional outcomes after ischemic str...
The DISTAL trial found that endovascular therapy in addition to best medical therapy did not reduce disability more than clot-busting treatment alone for patients with medium distal vessel blockages. The study showed that mechanical clot removal was a safe option, but its benefits were uncertain.
A new study led by UCL researchers has found that the GLP-1 drug exenatide has no positive impact on movement, symptoms, or brain imaging in people with Parkinson's disease. The trial involved 194 participants and ran for 96 weeks, with no benefits shown in any of these areas.
A new drug developed by the Centre for Addiction and Mental Health (CAMH) has shown significant promise in reversing memory loss in a mouse model of Alzheimer's disease. The drug, GL-II-73, selectively targets GABA receptors to restore brain function and repair damaged neural connections.
Researchers at the CNIC have designed a treatment strategy to protect the heart against cardiotoxic effects of anthracyclines, a common class of anticancer drugs. Empagliflozin, an SGLT2 inhibitor, has been shown to preserve cardiac function and metabolism in experimental models.
A narrative review of over 1,700 papers found only seven papers addressing dexamphetamine addiction directly. The study raises questions about the evidence underpinning its restriction by regulatory agencies. Dexamphetamine is effective in treating ADHD and narcolepsy but may have benefits in treating obesity.
A new study from the University of Birmingham found that digoxin is more effective than beta-blockers in reducing adverse events and hospital admissions for older patients with atrial fibrillation. This could lead to significant cost savings for the UK National Health Service, estimated at £102 million per year.
A major clinical trial has identified three new safe and effective regimens for treating drug-resistant tuberculosis, offering faster, safer, and more accessible care. The new treatments show promise in reducing treatment duration and side effects, making them a significant breakthrough in the fight against this infectious disease.
A new compound, V-161, has been discovered to effectively inhibit the growth of vancomycin-resistant Enterococci (VRE) by targeting a crucial enzyme. The study reveals that V-161 not only disrupts the enzyme function but also reduces VRE colonization in the mouse small intestine.
Insilico Medicine has successfully dosed the first patient in its global Phase I clinical trial of ISM6331, a potent pan-TEAD inhibitor. The treatment demonstrates superior efficacy and safety in preclinical studies, with potential synergistic anti-tumor effects and overcoming drug resistance.
This study investigated the feasibility of electroacupuncture-assisted ribavirin dosing in patients with long COVID, using Voll's electropuncture diagnostics. The results demonstrated that EAV can identify meridians with decreased electrodermal activity at acupuncture points, followed by medicament testing to measure daily doses.
Researchers found associations between antibiotics, antivirals, vaccines, and anti-inflammatory drugs with reduced dementia risk. The study pooled data from over 130 million individuals, identifying potential repurposed treatments for dementia.
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
A total of 105 compounds are identified from the SQ extract, with organic acids and amino acids dominating in the bloodstream. Pharmacokinetic profiles show dynamic changes in compound absorption and levels over time.
Researchers found that short-course antibiotics can be as effective as traditional longer treatments in preventing death and recurrence of pneumonia. This approach offers significant value for healthcare systems by reducing hospital expenditure while maintaining excellent patient outcomes.
This study investigates the biological mechanisms underlying incomplete immune reconstitution and evaluates Dihydroartemisinin's potential as a therapeutic agent. DHA effectively inhibits T cell activation in individuals with incomplete immune reconstitution, presenting a promising treatment strategy.
The study developed floating nanoballoons to improve ibuprofen's bioavailability and sustained release its anti-inflammatory effects. The formulation showed superior edema inhibition in acute inflammation studies, reducing TNF-α, hs-CRP, and IL-6 levels, while increasing anti-inflammatory IL-10 levels.
Researchers found that time in safe blood-sugar range can predict diabetes complications as accurately as hemoglobin A1c levels. The study used advanced machine learning techniques to analyze landmark diabetes data from the DCCT trial.
A clinical trial published in the New England Journal of Medicine showed that levofloxacin substantially reduced the risk of developing drug-resistant tuberculosis. The study found that levofloxacin reduced the risk of multidrug-resistant TB in adults and adolescents by 45 percent, and also significantly reduced the risk among family m...
Researchers found that carrots can enhance the body's ability to regulate blood sugar and positively influence the composition of gut bacteria. The study used mice with type 2 diabetes and found improved glucose tolerance after consuming carrot powder.
Research suggests ketamine use is increasing among US adults, linked to depression and sociodemographic factors. Expansion of prevention outreach and education on polydrug use harms are recommended.
Researchers have synthesized a molecule inspired by Nectandra leucantha and found it to be four times more potent than the prototype, killing Leishmania infantum selectively. The compound's bioavailability was improved, allowing it to circulate in the rat's organism for longer periods.
Researchers will analyze tissue samples from 100 patients over three years to understand why some respond better than others to biologic and targeted therapies. The study aims to improve matching of treatments to individual patients, reducing the guesswork and cost associated with ineffective treatment.
A recent case series suggests that an extended course of Paxlovid may help some patients with long Covid experience sustained improvements in their symptoms. The study, published in Communications Medicine, found that five out of 13 patients experienced significant symptom relief after taking the antiviral drug for 15 days.
Researchers analyzed data from over 700 patients with kidney injury and found that glucarpidase treatment improved kidney recovery rates. Glucarpidase rapidly clears methotrexate from the blood, reducing the risk of kidney toxicity.
The study identified 105 compounds in Shenqi Fuzheng extract, with organic acids and amino acids showing higher concentrations in the bloodstream. Compounds such as Astragalosides promptly enter the bloodstream within 5 minutes after administration.
Researchers provide comprehensive review of RSV's virology, clinical impact, and prevention strategies, emphasizing the need for effective vaccines to mitigate this critical health need. The review highlights RSV's severe impact on infants, children, and older adults, as well as its potential effects on multiple organs and systems.
A clinical trial showed that an antibody blocking Nogo-A protein improves motor function in patients with incomplete spinal cord injuries. The treatment led to significant improvements in voluntary muscle activation and everyday life functional independence. Further studies are needed to confirm the findings.
The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
A phase 1/2 clinical trial has demonstrated the safety and effectiveness of the AEF0217 molecule in improving cognitive function in people with Down syndrome. Measured outcomes showed significant improvements in behavioral skills, social interactions, and cognitive flexibility.
Longidaza significantly reduced exertional desaturation and dyspnea, as well as improved distance walked during the six-minute walk test. The drug's effects on exercise tolerance were sustained for over 100 days after treatment.
A new investigation by BMJ raises concerns over the PLATO trial that approved ticagrelor, citing discrepancies in data reporting and patient deaths. The study calls for a reappraisal of guidelines recommending the drug's use.
The Study of Tecovirimat for Mpox (STOMP) trial found that tecovirimat was safe but did not improve mpox resolution or pain in adults with mild to moderate clade II mpox. The study recommended stopping further enrollment due to the lack of efficacy signal.
Dana-Farber Cancer Institute researchers present promising results from two studies on systemic mastocytosis: a novel drug, bezuclastinib, shows early efficacy in treating advanced SM, while a new predictive tool distinguishes between life-threatening and less aggressive forms of the disease with high accuracy
A systematic review of 45 studies found inconsistent descriptions of psychotherapy sessions, making it difficult to replicate studies and compromise patient well-being. Researchers call for improved reporting standards to enhance the replicability, safety, and potential effectiveness of these therapies.
A phase 3 trial found that combining a second-generation BTK inhibitor, acalabrutinib, with a BCL-2 inhibitor, venetoclax, resulted in high progression-free survival rates and low toxicity. The treatment showed promise in treating chronic lymphocytic leukemia (CLL) patients.
Researchers at Tokyo University of Science have developed a new, highly selective and efficient method for synthesizing anti-cancer compounds. The innovative approach uses isopropyl magnesium bromide as a base to improve selectivity and scalability.
A review paper suggests that MDMA-assisted therapy can benefit military personnel with traumatic brain injuries, improving emotional and cognitive challenges. The drug may facilitate social connections, increased self-esteem, and neural plasticity, leading to improved treatment outcomes.
A large-scale clinical trial involving over 9,000 patients reveals that text message reminders failed to improve medication refill adherence over a year. The study included diverse representation from subgroups, including females, Hispanic ethnicity, and Spanish-speaking patients.
A clinical trial demonstrated the efficacy and tolerability of concizumab, a new drug for haemophilia patients, reducing bleeding rates. Concizumab works by blocking an anticoagulant factor, restoring the delicate balance between clotting and anti-clotting factors.
Researchers analyzed hundreds of malaria parasite genomes to identify genetic variants associated with drug resistance. The study's findings can help scientists predict antimalarial drug resistance and prioritize experimental treatments.
A new injection treatment has been found to reduce the need for further treatment by 30% compared to current steroid tablets. The treatment, benralizumab, targets specific white blood cells to reduce lung inflammation and improve symptoms.
The SONIA trial found that delaying and shortening CDK4/6 inhibitor treatment in patients with hormone receptor-positive advanced breast cancer leads to similar survival outcomes while reducing toxicity and cost by €45 million per year. This innovative approach could reduce the burden on healthcare systems worldwide.
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
A new study led by Weill Cornell Medicine found that tirzepatide reduced the risk of diabetes in obese and prediabetic patients by more than 90% after 176 weeks. The treatment also showed significant weight loss and improved blood sugar control.
A study estimates that approximately one-third of eligible US adults without diabetes were excluded from clinical trials supporting GLP-1 and GLP-1/GIP medications. The FDA should consider updating labeling to advise caution on generalizing these medications' safety and effectiveness to excluded populations.
Researchers at the University of Liverpool used AI to develop a personalised method for treating urinary tract infections, improving accuracy and reducing antibiotic resistance. The new approach uses real-time data to target specific bacterial infections, making antibiotics more effective.